Minimally Invasive Biomarker for Asthma Disease Severity



Status:Completed
Conditions:Asthma, Healthy Studies
Therapuetic Areas:Pulmonary / Respiratory Diseases, Other
Healthy:No
Age Range:18 - Any
Updated:2/8/2015
Start Date:July 2014
End Date:December 2014
Contact:Matthew A Rank, MD
Email:Rank.Matthew@mayo.edu
Phone:480-301-4284

Use our guide to learn which trials are right for you!

Feasibility of Using an Eosinophil-Specific Biomarker-(Eosinophil Peroxidase) in Clinical Practice

Can a clinical test be developed that could help manage asthma symptoms?

Project goals:

Develop a point-of-service assay to assess eosinophilic airway inflammation

Proposal Specific Aims:

1. To establish the infrastructure and test the feasibility of sputum collection in a
clinical setting as a minimally invasive patient sampling process for biomarker testing

2. To transform the laboratory-based eosinophil peroxidase (EPX) ELISA detection assay
into a clinic-friendly assessment that does not require sophisticated laboratory
equipment

Asthma subjects:

Inclusion

- Provider diagnosed asthma

- FeNO>50 ppb

- FEV1 > 1.0 Liter

Exclusion

- COPD by history

- Bronchiectasis by history

- Pregnant participants

Normal subjects:

Inclusion

- Age matched to asthma subjects

Exclusion

- Any eosinophil disorder by history

- Asthma by history

- Rhinitis or sinusitis by history
We found this trial at
1
site
13400 E. Shea Blvd.
Scottsdale, Arizona 85259
480-301-8000
Mayo Clinic Arizona Mayo Clinic in Arizona provides medical care for thousands of people from...
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials